Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2020.11818
Abstract: Importance Robust predictors for response to anti-programmed death 1 and its ligand (PD-1/PD-L1) immunotherapy in non-small cell lung cancer (NSCLC) are not fully characterized. Objective To evaluate whether PD-L1 (CD274) copy number gains (CNGs), comprising… read more here.
Keywords: nivolumab monotherapy; response; response nivolumab; programmed death ... See more keywords
Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-017-1118-x
Abstract: BackgroundCurrently, no markers predictive of response to nivolumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) are currently recognized in Japan. The present study was undertaken to identify such markers.Materials and methodsMedical records… read more here.
Keywords: treatment immediately; nivolumab monotherapy; response; response nivolumab ... See more keywords
Dissociated response and clinical benefit in patients treated with nivolumab monotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01077-7
Abstract: Immune checkpoint inhibitors (ICIs) are effective for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, an unconventional response pattern is sometimes encountered. A dissociated response (DR), characterized by some lesions shrinking and… read more here.
Keywords: nivolumab monotherapy; response; dissociated response; previously treated ... See more keywords
Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Targeted Oncology"
DOI: 10.1007/s11523-020-00716-y
Abstract: Background In 2017, nivolumab monotherapy was shown to be effective as third- or later-line therapy in patients with advanced gastric or gastroesophageal junction cancer. Objective In this study, we investigated the relationship between the neutrophil-to-lymphocyte… read more here.
Keywords: cancer; nivolumab monotherapy; patients gastric; nlr group ... See more keywords
Diffuse alveolar hemorrhage with nivolumab monotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2020.101131
Abstract: We describe a 60 year old man who developed respiratory insufficiency after treatment with 2 rounds of nivolumab monotherapy. Imaging revealed subtle ground glass infiltrates which progressed to diffuse opacities and consolidation. The patient was… read more here.
Keywords: hemorrhage; nivolumab monotherapy; diffuse alveolar; alveolar hemorrhage ... See more keywords
Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1974763
Abstract: AIMS Present cost-effectiveness analysis of nivolumab monotherapy vs commonly prescribed third-line (3L+) treatment in small cell lung cancer (SCLC). MATERIALS AND METHODS A three health states partitioned survival model (progression-free, progressed disease, and death; US… read more here.
Keywords: nivolumab monotherapy; line; treatment; cost ... See more keywords
The effect of proton pump inhibitors on the efficacy of nivolumab monotherapy in different types of cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz338.107
Abstract: Abstract Background Solid tumors are characterized by a highly acidic microenvironment that might hamper anti-cancer immunity. Several studies have shown that proton pump inhibitors (PPIs) can neutralize the pH of the tumor microenvironment and indirectly… read more here.
Keywords: pump inhibitors; nivolumab monotherapy; types cancer; ppis ... See more keywords
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials
Sign Up to like & getrecommendations! Published in 2018 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000467
Abstract: Nivolumab, a completely human programmed death-1 inhibitor antibody, was first approved by the Food and Drug Administration for patients with advanced malignant melanoma resistant to other modalities of treatment. In 2015, it received approval as… read more here.
Keywords: melanoma; nivolumab monotherapy; randomized controlled; combination ipilimumab ... See more keywords
Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Urology"
DOI: 10.1111/iju.14964
Abstract: To investigate the tumor shrinkage patterns of patients with metastatic renal cell carcinoma treated with nivolumab monotherapy. read more here.
Keywords: cell carcinoma; renal cell; nivolumab monotherapy; tumor shrinkage ... See more keywords
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-4115
Abstract: Abstract Purpose: MEDI0680 is a humanized anti–programmed cell death-1 (PD-1) antibody, and durvalumab is an anti-PD-L1 antibody. Combining treatment using these antibodies may improve efficacy versus blockade of PD-1 alone. This phase II study evaluated… read more here.
Keywords: cell; nivolumab monotherapy; durvalumab; combination ... See more keywords
Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4026
Abstract: 4026Background: In recent years, several studies suggest that neoadjuvant treatment improve outcomes of patients with resectable advanced gastric cancer (GC). In addition, nivolumab has demonstrate... read more here.
Keywords: patients resectable; neoadjuvant nivolumab; monotherapy patients; gastric cancer ... See more keywords